Oncogenic Ki-Ras regulates the expression of ISG15 and ISGylation, which in turn stabilizes Ki-Ras by inhibiting its degradation through lysosomes in breast cancer cells, suggesting that the ISGylation pathway is a key downstream mediator of oncogenic Ki-Ras. This evidence concerns the gene KRAS and breast carcinoma.